These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33570247)

  • 1. Efficacy of PARP inhibition combined with EZH2 inhibition depends on BRCA mutation status and microenvironment in breast cancer.
    Chen MK
    FEBS J; 2021 May; 288(9):2884-2887. PubMed ID: 33570247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer.
    Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC
    Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 4. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The PARP inhibitor AZD2281 (Olaparib) induces autophagy/mitophagy in BRCA1 and BRCA2 mutant breast cancer cells.
    Arun B; Akar U; Gutierrez-Barrera AM; Hortobagyi GN; Ozpolat B
    Int J Oncol; 2015 Jul; 47(1):262-8. PubMed ID: 25975349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP1 and PRC2 double deficiency promotes BRCA-proficient breast cancer growth by modification of the tumor microenvironment.
    Yang AY; Choi EB; So Park M; Kim SK; Park MS; Kim MY
    FEBS J; 2021 May; 288(9):2888-2910. PubMed ID: 33205541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination treatment using DDX3 and PARP inhibitors induces synthetic lethality in BRCA1-proficient breast cancer.
    Heerma van Voss MR; Brilliant JD; Vesuna F; Bol GM; van der Wall E; van Diest PJ; Raman V
    Med Oncol; 2017 Mar; 34(3):33. PubMed ID: 28138868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthetic Lethality of PARP Inhibition and Ionizing Radiation is p53-dependent.
    Sizemore ST; Mohammad R; Sizemore GM; Nowsheen S; Yu H; Ostrowski MC; Chakravarti A; Xia F
    Mol Cancer Res; 2018 Jul; 16(7):1092-1102. PubMed ID: 29592899
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PI3K inhibition impairs BRCA1/2 expression and sensitizes BRCA-proficient triple-negative breast cancer to PARP inhibition.
    Ibrahim YH; García-García C; Serra V; He L; Torres-Lockhart K; Prat A; Anton P; Cozar P; Guzmán M; Grueso J; Rodríguez O; Calvo MT; Aura C; Díez O; Rubio IT; Pérez J; Rodón J; Cortés J; Ellisen LW; Scaltriti M; Baselga J
    Cancer Discov; 2012 Nov; 2(11):1036-47. PubMed ID: 22915752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PARP inhibitor and immune checkpoint inhibitor have synergism efficacy in gallbladder cancer.
    Chen Y; Fan X; Lu R; Zeng S; Gan P
    Genes Immun; 2024 Aug; 25(4):307-316. PubMed ID: 38866965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The inhibition and treatment of breast cancer with poly (ADP-ribose) polymerase (PARP-1) inhibitors.
    De Soto JA; Wang X; Tominaga Y; Wang RH; Cao L; Qiao W; Li C; Xu X; Skoumbourdis AP; Prindiville SA; Thomas CJ; Deng CX
    Int J Biol Sci; 2006; 2(4):179-85. PubMed ID: 16810332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emerging strategies: PARP inhibitors in combination with immune checkpoint blockade in BRCA1 and BRCA2 mutation-associated and triple-negative breast cancer.
    Gupta T; Vinayak S; Telli M
    Breast Cancer Res Treat; 2023 Jan; 197(1):51-56. PubMed ID: 36318381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PARP inhibitor treatment of advanced breast cancer beyond the
    Yan F; Jiang Q; He M; Shen P
    Future Oncol; 2021 Jun; 17(18):2381-2393. PubMed ID: 33784822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advances in PARP inhibitors for the treatment of breast cancer.
    Dizdar O; Arslan C; Altundag K
    Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
    Madorsky Rowdo FP; Xiao G; Khramtsova GF; Nguyen J; Martini R; Stonaker B; Boateng R; Oppong JK; Adjei EK; Awuah B; Kyei I; Aitpillah FS; Adinku MO; Ankomah K; Osei-Bonsu EB; Gyan KK; Altorki NK; Cheng E; Ginter PS; Hoda S; Newman L; Elemento O; Olopade OI; Davis MB; Martin ML; Bargonetti J
    Cancer Lett; 2024 Mar; 584():216608. PubMed ID: 38199587
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging therapeutic modalities of PARP inhibitors in breast cancer.
    Wang X; Shi Y; Huang D; Guan X
    Cancer Treat Rev; 2018 Jul; 68():62-68. PubMed ID: 29870916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.